Research programme: colorectal cancer therapeutics - Second Genome/Mayo Clinic Center
Latest Information Update: 10 Oct 2014
At a glance
- Originator Second Genome
- Developer Mayo Clinic; Second Genome
- Class Peptides; Small molecules
- Mechanism of Action Metagenome modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Colorectal cancer